Table 1:
Demographic and clinical data of the patient population at baseline.
| Gender (M/F) | 19 M/1 F |
| Age (years) | 54.3 ± 16.5 |
| Dry body weight (kg) | 77.9 ± 16.2 |
| Dialysis vintage (months) | 27.4 (16.5; 66.6) |
| Renal disease | IgA nephropathy (n = 4); renal cell carcinoma (n = 4); autosomal dominant polycystic kidney disease (n = 2); interstitial nephritis (n = 2); diabetic nephropathy (n = 1); lithium nephropathy (n = 1); HIV-associated nephropathy (n = 1); CAKUT (n = 1); focal segmental glomeruloscleroses (n = 1); bilateral reflux (n = 1); granulomatosis with polyangiitis (n = 1); nephronophthisis (n = 1) |
| Vascular access | Arterio-venous fistula (n = 14); central venous catheter (n = 6) |
| Anticoagulation dose | Enoxaparin 40 mg (n = 1); 60 mg (n = 9); 80 mg (n = 10); 100 mg (n = 1) |
| Platelet inhibitors | Acetylsalicylic acid: 80 mg (n = 6); 100 mg (n = 1) |
| Hb (g/dL) | 12.2 (10.9; 12.5) |
| Platelet count (10³/µL) | 213 ± 74 |
| aPTT (s) | 36.9 (34.6; 40.7) |
| INR (–) | 0.96 (0.92; 1.02) |
| AT (%) | 88.6 ± 10.5 |
| CRP (mg/L) | 7.0 (3.2; 12.3) |
Data are presented as mean ± standard deviation or median (25th pct; 75th pct).
M: male; F: female; CAKUT: congenital anomalies of the kidney and urinary tract; IgA: immunoglobulin A; Hb: hemoglobin; INR: international normalized ratio; AT: antithrombin; CRP: C-reactive protein.